27 - 29 September, 2010, Mövenpick Hotel Amsterdam City Centre, Amsterdam
Download the Brochure
Become a Pharma IQ Member and receive our weekly newsletter!
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
Dr Tran Pham
Pharmorphix is one of Europe’s leading providers of solid-form research services to the international pharmaceutical and biotech industries. The ability to prepare co-crystals in significant quantities is one of the major challenges that still need to be overcome in order for this field to become an economically viable method of producing new drug products. Pharmorphix laboratories investigates how both traditional and new methodologies can be employed to overcome these problems.
Dr Christopher Frampton
Chief Scientific Officer
Dr Michael-Robin Witt
Chief Technology Officer
The unique chemical nature of co-crystals and their beneficial pharmacological properties provide good arguments for their patentability. A robust co-crystal patent application must draw upon that unique chemical nature and beneficial pharmacological properties while at the same time marshal that information to form a legal document ready for rigorous examination. Co-crystal patent applications can also lend themselves well to expedited patent procedures such that the examination process may be shortened and the patent granted sooner. But, this takes planning.
Participants will learn about:
Dr Jeffrey Lindeman
J.A. Lindeman & Co. PLLC
Dr Richard Schartman
Bristol Myers Squibb
The importance of pharmaceutical co-crystals lies in the ability to engineer properties such as solubility, dissolution, bioavailability and stability. A key question that arises with these materials is: what is the true solubility of the co-crystal, and how does it correlate with its components and its performance? Some co-crystals transform to API crystals in the presence of water and deliberate efforts are required to prevent this transformation, while others remain in the co-crystal phase.This talk will present approaches that are valuable to predict co-crystal-solution phase behaviour and guide co-crystal selection without the time and material consuming requirements of traditional methods.
Associate Professor, Dept. of Pharmaceutical Sciences
University of Michigan
Dr Mark Oliveira
While single crystal X-ray diffraction tells us much about the average bulk structure of an organic crystal (single and multi-component) we also need to appreciate that stability will be affected by the nature of the exposed crystal surfaces as well as any crystalline imperfections present in the solid. The talk will review:
Professor William Jones
Head of Materials Chemistry Group
University of Cambridge
Mr Bertrand Gellie
The European Patent Office (EPO)
[ Register Now ]
Questions? Contact us on 0800 652 2363 or +44 (0) 20 7368 9300 or email email@example.com now!